These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 17634624)

  • 1. Arsenic metabolism in multiple myeloma and astrocytoma cells.
    Falnoga I; Slejkovec Z; Pucer A; Podgornik H; Tusek-Znidaric M
    Biol Trace Elem Res; 2007 Apr; 116(1):5-28. PubMed ID: 17634624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
    Sahu GR; Jena RK
    Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elimination of the differential chemoresistance between the murine B-cell lymphoma LY-ar and LY-as cell lines after arsenic (As2O3) exposure via the overexpression of gsto1 (p28).
    Giri U; Terry NH; Kala SV; Lieberman MW; Story MD
    Cancer Chemother Pharmacol; 2005 Jun; 55(6):511-21. PubMed ID: 15761769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment.
    Wang Z; Zhou J; Lu X; Gong Z; Le XC
    Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metal binding of metallothioneins in human astrocytomas (U87 MG, IPDDC-2A).
    Znidaric MT; Pucer A; Fatur T; Filipic M; Scancar J; Falnoga I
    Biometals; 2007 Oct; 20(5):781-92. PubMed ID: 17115260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic enhances the activation of Stat1 by interferon gamma leading to synergistic expression of IRF-1.
    Chelbi-alix MK; Bobé P; Benoit G; Canova A; Pine R
    Oncogene; 2003 Dec; 22(57):9121-30. PubMed ID: 14668793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide.
    Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K
    Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
    Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
    Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Arsenic Trioxide inhibits the growth of human ovarian carcinoma cell line.
    Bornstein J; Sagi S; Haj A; Harroch J; Fares F
    Gynecol Oncol; 2005 Dec; 99(3):726-9. PubMed ID: 16243384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arsenic trioxide in environmentally and clinically relevant concentrations interacts with calcium homeostasis and induces cell type specific cell death in tumor and non-tumor cells.
    Florea AM; Büsselberg D
    Toxicol Lett; 2008 Jun; 179(1):34-42. PubMed ID: 18485628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines.
    Ryu KH; Woo SY; Lee MY; Jung YJ; Yoo ES; Seoh JY; Kie JH; Shin HY; Ahn HS
    Pediatr Hematol Oncol; 2005; 22(7):609-21. PubMed ID: 16166054
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
    Liu B; Pan S; Dong X; Qiao H; Jiang H; Krissansen GW; Sun X
    Cancer Sci; 2006 Jul; 97(7):675-81. PubMed ID: 16827809
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice.
    Rousselot P; Larghero J; Labaume S; Poupon J; Chopin M; Dosquet C; Marolleau JP; Janin A; Brouet JC; Fermand JP
    Eur J Haematol; 2004 Mar; 72(3):166-71. PubMed ID: 14962234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma.
    Wu KL; Beksac M; van Droogenbroeck J; Amadori S; Zweegman S; Sonneveld P
    Haematologica; 2006 Dec; 91(12):1722-3. PubMed ID: 17145617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
    Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen Z
    Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase 2 study of arsenic trioxide in patients with relapsed or refractory multiple myeloma.
    Hussein MA; Saleh M; Ravandi F; Mason J; Rifkin RM; Ellison R
    Br J Haematol; 2004 May; 125(4):470-6. PubMed ID: 15142117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
    Wang X; Wang G; Dong D; Fu S; Yang B
    Exp Toxicol Pathol; 2008 Sep; 60(6):481-8. PubMed ID: 18606528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimony-trioxide- and arsenic-trioxide-induced apoptosis in myelogenic and lymphatic cell lines, recruitment of caspases, and loss of mitochondrial membrane potential are enhanced by modulators of the cellular glutathione redox system.
    Lösler S; Schlief S; Kneifel C; Thiel E; Schrezenmeier H; Rojewski MT
    Ann Hematol; 2009 Nov; 88(11):1047-58. PubMed ID: 19301004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicity of dimethylmonothioarsinic acid toward human epidermoid carcinoma A431 cells.
    Naranmandura H; Ibata K; Suzuki KT
    Chem Res Toxicol; 2007 Aug; 20(8):1120-5. PubMed ID: 17630711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tissue distribution of arsenic species in rabbits after single and multiple parenteral administration of arsenic trioxide: tissue accumulation and the reversibility after washout are tissue-selective.
    Lin CJ; Wu MH; Hsueh YM; Sun SS; Cheng AL
    Cancer Chemother Pharmacol; 2005 Feb; 55(2):170-8. PubMed ID: 15322825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.